‘Major step forward’ as new treatment for advanced cancer is fast-tracked
Since a new treatment for widespread use in NHS is approved, renewed optimism was offered to women struggling with an advanced uterine cancer. Only 15% of women survive for five years after the diagnosis of endometrial cancer, which is typically a cancer caused by the lining of the uterus.
According to health authorities, treatment can slow down cancer growth and increase survival rates. The National Institute of Health and Care Excellence (NICE) predicts that approximately 2,100 women will benefit from this treatment per year.
Nice, the UK NHS treatment approved, such cancers to treat women with “a step forward” said. The treatment, also known as Keytruda and produced by Merck Sharp and Dohme, is an immunotherapy medication applied by a drip with chemotherapy drugs carboplatin and Paklitaksel and can be given up to two years.
According to Nice, clinical studies have shown that combination of treatments reduces the risk of death by 26% only compared to chemotherapy. Treatments can also slow down cancer progression.
Nice, Drug Evaluation Director Helen Knight, “For people with advanced endometrial cancer, this innovative combination offers a strong treatment option.” He said. He continued: “We are taking a big step in the next and we are pleased to recommend it as part of our commitment to obtain the best care of people by providing the value of the taxpayer.”
Approximately 9,700 women reported that endometrial cancer was diagnosed annually, and Nice determined this as the most common gynecological malignancy of England.
“Primary or repetitive uterine (endometrial) cancer has a major impact on the quality of life for those diagnosed. The great news in which this new treatment is approved, will improve their improvement and improvement exits for those who are approved.”
“This treatment is to help thousands of women to live longer, to spend more time with your loved ones, and to spend more time with your loved ones, and the cancer drug fund, which will help thousands of women to live longer as possible, and NHS is rapidly monitored with routine use to the patient.”
